A founder still runs the company he built from scratch in 1987, controls more than four-fifths of its shares, and sells chemotherapy drugs, blood products, and biosimilars to hospitals across Latin America — yet the stock trades at less than a third of its 2021 IPO price, leaving a recovery story that the market has not yet priced in. Full nameBlau Farmacêutica S.A. Ticker / exchangeBLAU3 — B3 (Novo Mercado), São Paulo HeadquartersCotia, São Paulo, Brazil SectorHealthcare — Specialty & Generic Drug Manufacturers Employees~1,700 (per latest available disclosure) Market value …
Company Intelligence — Institutional Access
This dossier is part of our Company Intelligence database.
Full profiles, exchange dossiers and the regional intelligence briefs are available to institutional subscribers. Professional from US$490/year, Corporate US$1,450, Institutional US$3,900.
See institutional access →Already a subscriber? Log in.
Part of LatAm Company Intelligence
This company profile belongs to The Rio Times' research on every listed company and exchange in Latin America and the Caribbean. Browse the full intelligence hub →
Latest coverage
Brazil’s Blau Farmacêutica Profit Drops 34% on Tender Delay but Biotech Pipeline Accelerates
Blau Farmacêutica, GPA, and Fleury in Q3 2025: Growth, Challenges, and Strategic Moves
Financial Performance of Blau Farmacêutica, Estapar, and InterCement in Q4 2024
Read More from The Rio Times
The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →